EPS Creative Health Technology Group (HKG:3860) entered into an MoU with seller Honestar Medical to potentially acquire a 16.23% stake in China Genetic for between around HK$40 million to HK$45 million, according to a Tuesday Hong Kong bourse filing.
The parties will engage in negotiations and potentially enter into a formal agreement by March 6.
China Genetic engages in the in-house R&D, manufacturing, and sales of biopharmaceutical products in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.